KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Non-Current Deffered Revenue (2018 - 2021)

Historic Non-Current Deffered Revenue for Castle Biosciences (CSTL) over the last 4 years, with Q3 2021 value amounting to $986000.0.

  • Castle Biosciences' Non-Current Deffered Revenue fell 1350.88% to $986000.0 in Q3 2021 from the same period last year, while for Sep 2021 it was $986000.0, marking a year-over-year decrease of 1350.88%. This contributed to the annual value of $1.7 million for FY2020, which is 305454.55% up from last year.
  • As of Q3 2021, Castle Biosciences' Non-Current Deffered Revenue stood at $986000.0, which was down 1350.88% from $963000.0 recorded in Q2 2021.
  • Over the past 5 years, Castle Biosciences' Non-Current Deffered Revenue peaked at $1.7 million during Q4 2020, and registered a low of $44000.0 during Q4 2018.
  • Moreover, its 4-year median value for Non-Current Deffered Revenue was $941000.0 (2020), whereas its average is $638699.6.
  • As far as peak fluctuations go, Castle Biosciences' Non-Current Deffered Revenue soared by 305454.55% in 2020, and later plummeted by 1350.88% in 2021.
  • Quarter analysis of 4 years shows Castle Biosciences' Non-Current Deffered Revenue stood at $44000.0 in 2018, then rose by 25.0% to $55000.0 in 2019, then soared by 3054.55% to $1.7 million in 2020, then plummeted by 43.17% to $986000.0 in 2021.
  • Its Non-Current Deffered Revenue stands at $986000.0 for Q3 2021, versus $963000.0 for Q2 2021 and $995000.0 for Q1 2021.